Tokyo, Dec. 15 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000059996) titled 'Sarcopenia and its natural trajectories with prospective multicenter analysis in older patients with heart failure from the northern Japanese region' on Dec. 15.

Study Type: Observational

Primary Sponsor: Institute - Department of Rehabilitation, Sapporo Medical University School of Medicine

Condition: Condition - Heart failure Classification by malignancy - Others Genomic information - NO

Objective: Narrative objectives1 - The objective of this multi-center prospective observational study is to quantitatively assess the dynamic changes (trajectories) of sarcopenia (SP) in elderly heart failure (HF) patients, utilizing an HF-specific estimated Appendicular Skeletal Muscle Mass (ASMI) assessment method developed by the investigators. Furthermore, the study aims to verify the association between the temporal change in SP and long-term prognosis (including all-cause mortality and HF rehospitalization) following discharge. Basic objectives2 - Others

Eligibility: Age-lower limit - 65 years-old <= Age-upper limit - Not applicable Gender - Male and Female Key inclusion criteria - 1. Patients aged 65 years or older 2. Admitted for decompensated heart failure 3. Able to ambulate independently at discharge 4. Heart failure diagnosed according to the Japanese Circulation Society/Japanese Heart Failure Society Guidelines 5. Provision of written informed consent for study participation Key exclusion criteria - 1. low serum BNP (<100pg/ml) / NT-pro BNP (<300pg/ml) level on admission 2. Planned valvular surgical procedures at discharge 3. Pulmonary arterial hypertension 4. Chronic thromboembolic pulmonary hypertension 5. Chronic dialysis or planned initiation of dialysis at discharge 6. Planned or undergone heart transplantation or left ventricular assist device 7. Acute myocarditis 8. Peripheral arterial disease (Rutherford classification I-IV) 9. Central or peripheral neurological disorders affecting muscle function 10. Severe arthritis or orthopedic conditions limiting physical assessment 11. Active malignancy or systemic inflammatory conditions 12. Unable to complete SWE measurements 13. Life expectancy < 1 year due to non-cardiac conditions 14. Participation in other interventional clinical trials Target Size - 1000

Recruitment Status: Recruitment status - Open public recruiting Date of protocol fixation - 2025 Year 11 Month 01 Day Date of IRB - 2025 Year 06 Month 12 Day Anticipated trial start date - 2025 Year 12 Month 01 Day Last follow-up date - 2030 Year 05 Month 12 Day

To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000068572

Disclaimer: Curated by HT Syndication.